首页> 外文期刊>Journal of Clinical Microbiology >Modified CLSI Extended-Spectrum β-Lactamase (ESBL) Confirmatory Test for Phenotypic Detection of ESBLs among Enterobacteriaceae Producing Various β-Lactamases
【24h】

Modified CLSI Extended-Spectrum β-Lactamase (ESBL) Confirmatory Test for Phenotypic Detection of ESBLs among Enterobacteriaceae Producing Various β-Lactamases

机译:改良的CLSI广谱β-内酰胺酶(ESBL)确证试验用于表型检测产各种β-内酰胺酶的肠杆菌科细菌中的ESBLs

获取原文
           

摘要

The worldwide dissemination of Enterobacteriaceae producing AmpC β-lactamases and carbapenemases makes difficult the phenotypic detection of extended-spectrum β-lactamases (ESBLs), as they may be masked by these additional enzymes. A modification of the CLSI ESBL confirmatory test was developed and evaluated in a comparative study for its ability to successfully detect ESBLs among Enterobacteriaceae producing various carbapenemases (Klebsiella pneumoniae carbapenemase [KPC], VIM, NDM, and OXA-48) and plasmidic or derepressed AmpCs. The modified CLSI ESBL confirmatory test was performed with cefotaxime and ceftazidime disks with and without clavulanate, on which both boronic acid (BA) and EDTA were dispensed. A total of 162 genotypically confirmed ESBL-positive Enterobacteriaceae isolates (83 carbapenemase/ESBL producers, 25 AmpC/ESBL producers, and 54 ESBL-only producers) were examined. For comparison, 139 genotypically confirmed ESBL-negative Enterobacteriaceae isolates (94 of them possessed carbapenemases and 20 possessed AmpCs) were also tested. The standard CLSI ESBL confirmatory test was positive for 106 of the 162 ESBL producers (sensitivity, 65.4%) and showed false-positive results for 4 of the 139 non-ESBL producers (specificity, 97.1%). The modified CLSI ESBL confirmatory test detected 158 of 162 ESBL producers (sensitivity, 97.5%) and showed no false-positive results for non-ESBL producers (specificity, 100%). The findings of the study demonstrate that the modified CLSI ESBL confirmatory test using antibiotic disks containing both BA and EDTA accurately detects ESBLs in Enterobacteriaceae regardless of the coexistence of additional β-lactam resistance mechanisms.
机译:产肠杆菌科细菌的AmpCβ-内酰胺酶和碳青霉烯酶在世界范围内的传播使扩展谱β-内酰胺酶(ESBLs)的表型检测变得困难,因为它们可能被这些额外的酶所掩盖。对CLSI ESBL验证测试的一种改进方法进行了开发,并在一项比较研究中进行了评估,以评估它能够成功检测肠杆菌科细菌中产生各种碳青霉烯酶(肺炎克雷伯菌碳青霉烯酶[KPC],VIM,NDM和OXA-48)以及质粒或抑制的AmpCs 。修改后的CLSI ESBL验证测试是使用头孢噻肟和头孢他啶圆盘(含或不含克拉维酸盐)进行的,在盘上均分配了硼酸(BA)和EDTA。总共检查了162个基因型已确认的ESBL阳性肠杆菌科细菌分离株(83个碳青霉烯酶/ ESBL生产者,25个AmpC / ESBL生产者和54个仅ESBL的生产者)。为了进行比较,还测试了139个基因型确认的ESBL阴性肠杆菌科细菌(其中94个具有碳青霉烯酶和20个具有AmpC)。标准的CLSI ESBL确认性测试对162个ESBL生产者中的106个阳性(敏感性,占65.4%),对139个非ESBL生产者中的4个,其假阳性结果(特异性,占97.1%)。修改后的CLSI ESBL确证测试检测到162个ESBL生产者中的158个(敏感性,为97.5%),未显示非ESBL生产者的假阳性结果(特异性为100%)。研究结果表明,使用包含BA和EDTA的抗生素光盘进行的改良的CLSI ESBL确证试验,无论是否存在其他β-内酰胺耐药机制,都可准确检测肠杆菌科细菌中的ESBLs。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号